<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="142905">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01883284</url>
  </required_header>
  <id_info>
    <org_study_id>8870</org_study_id>
    <nct_id>NCT01883284</nct_id>
  </id_info>
  <brief_title>Action of Epigenetic Modifiers in Cystic Fibrosis Treatment: ex Vivo Model of Nasal Epithelium of CF Patients</brief_title>
  <acronym>Mod2EpiCF</acronym>
  <official_title>Action of Epigenetic Modifiers in Cystic Fibrosis Treatment: ex Vivo Model of Nasal Epithelium of CF Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <authority>France: Committee for the Protection of Personnes</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Epigenetic modifiers has been showed to rescue F508del-CFTR channel to apical membrane of
      epithelial cell lines. In this study, the investigators evaluate epigenetic modifiers
      effects firstly on CFTR rescue, then on secretion and synthesis of inflammatory factors
      (IL-8, LXA4 and SCGB1A1) and mucines (MUC5AC and MUC5B) in a dynamic epithelium model using
      an air-liquide interface culture of nasals cells from CF patients or controls.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Mature CFTR protein percentage variation after in vitro epigenetics modifiers treatment</measure>
    <time_frame>24 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pro-inflammatory cytokines number variations after epigenetic modifiers treatment</measure>
    <time_frame>24 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-inflammatory cytokines number variations after epigenetic modifiers treatment</measure>
    <time_frame>24 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mucin composition variations after epigenetic modifiers treatment</measure>
    <time_frame>24 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Cystic Fibrosis</condition>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>Cystic Fibrosis patients (CF)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tests in vitro after sampling nasal cells of CF patients or controls are the intervention done on these subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control subjects (non CF)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Tests in vitro after sampling nasal cells of CF patients or controls are the intervention done on these subjects</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Tests in vitro after sampling nasal cells of CF patients or controls</intervention_name>
    <description>Nasal cells of CF patients or controls were collected by scratching of intermediate turbinate and cultured in vitro. Epigenetic modifiers treatment was applied to these ex vivo nasal epithelia. Then, mRNA, protein and secretions were quantified.</description>
    <arm_group_label>Cystic Fibrosis patients (CF)</arm_group_label>
    <arm_group_label>Control subjects (non CF)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        General inclusion criteria :

          -  informed consent

          -  benefit from disease insurance regimen

          -  men and women

        Inclusion Criteria for CF patients

          -  2 severe CF mutations

          -  age superior or equal to 12

        Inclusion Criteria for controls :

          -  age superior or equal to 18

          -  no smoker (for 5 years)

        General exclusion criteria :

          -  participation to an other interventionnal study

          -  subject in exclusion period

          -  law protected subject

          -  pregnant and breast fooding

        Specific Exclusion Criteria:

          -  Xylocaine hypersensibility

          -  Porphyria

          -  severe hepatic failure

          -  Epilepsy

          -  Severe cardiac failure

          -  local anesthesic contra indication

        Specific Control subject Exclusion Criteria:

          -  respiratory disease

          -  cystic fibrosis

          -  acute infection &lt; 6 weeks

          -  on treatment

          -  antibiotic treatment &lt; 3 months
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raphaël RC CHIRON, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Arnaud de Villeneuve CHU Montpellier</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nicolas MOLINARI, PhD</last_name>
    <phone>(+33)467338979</phone>
    <email>nicolas.molinari@inserm.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Respiratory Diseases Department</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raphaël CHIRON, MD</last_name>
      <phone>(+33)467336089</phone>
      <email>r-chiron@chu-montpellier.fr</email>
    </contact>
    <contact_backup>
      <last_name>Anne BERGOUGNOUX, PhD</last_name>
      <phone>(+33)411759879</phone>
      <email>anne.bergougnoux@inserm.Fr</email>
    </contact_backup>
    <investigator>
      <last_name>Raphaël RC CHIRON, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Arnaud AB BOURDIN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <lastchanged_date>June 20, 2013</lastchanged_date>
  <firstreceived_date>June 13, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cystic Fibrosis</keyword>
  <keyword>nasal epithelia</keyword>
  <keyword>mucins</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
